Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy

Pharmacogenetics. 1995 Dec;5(6):389-92. doi: 10.1097/00008571-199512000-00008.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Anticoagulants / administration & dosage*
  • Anticoagulants / metabolism*
  • Aryl Hydrocarbon Hydroxylases*
  • Base Sequence
  • Cytochrome P-450 CYP2C9
  • Cytochrome P-450 Enzyme System / genetics*
  • Cytochrome P-450 Enzyme System / metabolism*
  • DNA Primers / genetics
  • Female
  • Humans
  • Male
  • Molecular Sequence Data
  • Pharmacogenetics
  • Polymerase Chain Reaction
  • Polymorphism, Genetic*
  • Steroid 16-alpha-Hydroxylase*
  • Steroid Hydroxylases / genetics*
  • Steroid Hydroxylases / metabolism*
  • Warfarin / administration & dosage*
  • Warfarin / metabolism*

Substances

  • Anticoagulants
  • DNA Primers
  • Warfarin
  • Cytochrome P-450 Enzyme System
  • Steroid Hydroxylases
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Steroid 16-alpha-Hydroxylase